We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




New Antibiotic Kills Pathogens Without Detectable Resistance

By HospiMedica International staff writers
Posted on 20 Jan 2015
The first new antibiotic to be discovered in nearly 30 years could revolutionize the fight against the growing antibiotic resistance, claims a new study.

Researchers at the University of Bonn (Germany), Northeastern University (Boston, MA, USA), and other institutions have discovered a new antibiotic, which they named teixobactin, which inhibits cell wall synthesis by binding to lipid II, and is different in its action than other glycopeptide drugs, such as vancomycin or dalbavancin. More...
Teixobactin was highly effective against common Gram positive bacteria, such as Clostridium difficile, Mycobacterium tuberculosis, and Staphylococcus aureus, but was ineffective against Gram negative pathogens.

The discovery was made possible using a new technique called the iChip, which is made of a lattice of wells holding individual bacteria within agar. Once loaded with bacteria, the iChip is covered with a permeable membrane and replaced into the original soil. Using the technique, the researchers were able to screen 10,000 previously unculturable bacteria, discovered a new bacteria, Eleftheria terrae, and 25 new compounds, among them teixobactin, the most promising one to date.

In mouse studies, teixobactin showed 100% efficacy against methicillin-resistant Staphylococcus aureus (MRSA) sepsis in thigh infection, and was very active against S. pneumoniae in lungs. No toxicity and no hemolytic activity were seen against the mammal cells tested, and the drug did not bind DNA, leading the researchers to be optimistic about its overall toxicity. The first clinical trials on humans could begin in two years and, if successful, the drug could be in widespread use in 10 years. The study describing teixobactin and the iChip was published on January 7, 2015, in Nature.

“Bacteria develop resistance by mutations in their proteins. The targets of teixobactin are not proteins, they are polymer precursors of cell wall building blocks so there is really nothing to mutate,” said senior author, Prof. Kim Lewis, PhD, director of the antimicrobial discovery center at Northeastern University. “Apart from the immediate implementation, there is also, I think, a paradigm shift in our minds, because we have been operating on the basis that resistance development is inevitable and that we have to focus on introducing drugs faster than resistance.”

The “golden age” of antibiotic discovery was achieved by screening soil microorganisms, but this limited resource of cultivable bacteria was overmined by the 1960s, since 99% of microbes will not grow in laboratory conditions. The advent of the iChip could aid growing the microbes in the soil, and then isolating their antibiotic chemical compounds.

Related Links:

University of Bonn
Northeastern University



Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Medical Monitor
SILENIO D
Silver Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.